Antithrombin concentrate with plasma exchange in purpura fulminans

Munteanu, Carmen; Bloodworth, L L; Korn, Thomas H. E.

doi:10.1097/00130478-200007000-00016

Cited by 16 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most survivors were treated with TPE within 12 h of the onset of MSOF; patients with delayed TPE had much poor survival (Table III) [22]. The overall survival for the 60 patients from 11 series was 82% (49/60) (Table III) [18–27]. Our data expands previous published series and provides further support for early TPE in severe sepsis‐induced MSOF.…”

Section: Discussionsupporting

confidence: 62%

Outcomes of previously healthy pediatric patients with fulminant sepsis‐induced multisystem organ failure receiving therapeutic plasma exchange

Kiss

Dargo

et al. 2011

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 62%

Outcomes of previously healthy pediatric patients with fulminant sepsis‐induced multisystem organ failure receiving therapeutic plasma exchange

Kiss

Dargo

et al. 2011

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

“…Simultaneous to enhanced fibrin production, attenuated fibrinolysis caused by increased plasminogen activator inhibitor type 1 (PAI-1), as well as dysfunction and/or depletion of natural anti-coagulants [antithrombin III, protein C, protein S and tissue factor pathway inhibitor (TFPI)] occurs. A correlation between low AT III and mortality in sepsis provided the impetus for studying AT III replacement; however, no consistent benefit has been observed in either adults 84–87, children 88, 89, or neonates 90.…”

Section: Key Developmental Differences Impacting Neonatal and Pediatrmentioning

confidence: 99%

The Host Response to Sepsis and Developmental Impact

et al. 2010

View full text Add to dashboard Cite

Invasion of the human by a pathogen necessitates an immune response to control and eradicate it. When this response is inadequately regulated, systemic manifestations can result commonly manifested in physiologic changes described as "sepsis". Recognition, diagnosis, and management of sepsis remain among the greatest challenges shared by the fields of neonatology and pediatric critical care medicine. Sepsis remains among the leading causes of death in both developed and under-developed countries with an incidence that is predicted to increase each year. Despite these sobering statistics, promising therapies derived from pre-clinical models have universally failed to obviate the substantial mortality and morbidity associated with sepsis. Thus, there remains a need for well-designed epidemiologic and mechanistic studies of neonatal and pediatric sepsis to improve our understanding of the causes-both early and late-of deaths attributed to the syndrome. In reviewing the definitions and epidemiology, developmental influences and regulation of the host response to sepsis, it is anticipated that an improved understanding of this host response will assist clinician-investigators in identifying improved therapeutic strategies. Keywords sepsis; septic shock; developmental influence; hemodynamics; coagulation cascade; immune function Definitions characterizing the host responses in sepsis"Sepsis" referring to the "decomposition of animal or vegetable organic matter in the presence of bacteria" 1 first appeared over 2700 years ago in the poems of Homer. Hippocrates also used the term "sepsis" and believed the decomposition could release "dangerous principles" that could cause "auto-intoxication" 2 . Lewis Thomas furthered this concept when he proposed that the clinical responses seen in sepsis were the result of the host's response to the infectious agent 3 . In 1991, an American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference was convened to create a framework in which to define the systemic response to sepsis which resulted in defining criteria for the systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock 4, 5 . These criteria were refined a decade later (2001) Through clinical observations, pediatricians and neonatologists had recognized that the systemic inflammatory response of tachycardia, tachypnea, hyperthermia and leukocytosis (Table 1) most commonly triggered by infection, could also be present following trauma, burn injury, pancreatitis and various other insults. As a result, this physiologic response was defined as the systemic inflammatory response syndrome (SIRS) with no reference to the presence of infection. Sepsis was defined as a SIRS response associated with infection based on either microbiologic cultures or strong clinical evidence of the presence of an infection. Severe sepsis was defined as sepsis plus evidence of organ dysfunction define around pediatric parameters (Table 2) while septic shock was defined as sepsis criteria ...

show abstract

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue

Schwartz

Winters

Padmanabhan

et al. 2013

J of Clinical Apheresis

560

769

View full text Add to dashboard Cite

The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is charged with reviewing, updating and categorizating indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (Fourth Edition), the committee has incorporated systematic review and evidence-based approach in the grading and categorization of indications. This Sixth Edition of the ASFA Special Issue has further improved the process of using evidence-based medicine in the recommendations by consistently applying the category and GRADE system definitions, but eliminating the "level of evidence" criteria (from the University HealthCare Consortium) utilized in prior editions given redundancy between GRADE and University HealthCare Consortium systems. The general layout and concept of a fact sheet that was utilized in the Fourth and Fifth Editions, has been largely maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis in a specific disease entity. This article consists of 78 fact sheets (increased from 2010) for therapeutic indications in ASFA categories I through IV, with many diseases categorized having multiple clinical presentations/situations which are individually graded and categorized.

show abstract

Antithrombin concentrate with plasma exchange in purpura fulminans

Cited by 16 publications

References 18 publications

Outcomes of previously healthy pediatric patients with fulminant sepsis‐induced multisystem organ failure receiving therapeutic plasma exchange

Outcomes of previously healthy pediatric patients with fulminant sepsis‐induced multisystem organ failure receiving therapeutic plasma exchange

The Host Response to Sepsis and Developmental Impact

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue

Contact Info

Product

Resources

About